(3) A disorder involving body volume receptors: This is a very hypothetical disorder but we have investigated one patient following an infusion of 48 g albumin as a 10% solution. This resulted in a temporary elevation of plasma volume as shown by a fall in the PCV. However, after five days the situation had returned to its pre-existing state and it would therefore appear that some mechanism regulating plasma volume was set at a permanently lower level than normal.
(4) Aldosterone excretion: Relevant to plasma volume maintenance could be the production and excretion of aldosterone and with the help of Dr E J Ross we have measured the twenty-four-hour excretion of aldosterone in our pseudopolycythaemic patients whilst on their normal diets and compared these with a group of polycythemics with normal plasma volume. All except one of these patients showed a significant reduction in aldosterone excretion and, what is perhaps more significant, they failed to respond to three days of salt restriction, on a diet containing less than 0 5 g of salt, by increasing their aldosterone excretion in the manner of normal subjects. The administration of aldosterone in a dose of 0-5 mg daily for three days resulted in one patient in a fall in hmematocrit as might be expected, although the patient did not feel any benefit. How these investigations are related to the cause of this condition remain to be seen but they provide a possible lead to further investigations which we are following.
The last point about the diagnosis of polycythaemia rubra vera which I wish to make is with regard to the condition myeloid metaplasia. Most of us are aware of the existence of a group of polycythamics with gross hepatosplenomegaly and often leucocytosis and thrombocythimia.
These patients show evidence of myeloid metaplasia on liver biopsy and if their course is followed over a number of years they may pass into a phase of marrow failure with fibrosis or leukaemia. What concerns me about this group of patients is whether, in any survey of the course of polycythiemia rubra vera, they should be included or excluded, as they would clearly influence the prognosis of the whole group under study. The tendency is to regard them as one extreme of the spectrum of patients with primary polycythimia but if their prognosis differs radically from the others, as I suspect it does, then it may be important to group our polycythemic patients separately.
Dr D G Penington (London Hospital, London) The Relation of Erythropoietin to Polycythiemia The concept of a humoral mechanism for the regulation of red cell production dates from the studies of Carnot & Deflandre (1906) . Although later workers were unable to reproduce their findings, they claimed that plasma from anemic animals stimulated erythropoiesis when injected into normal recipients. The existence of such a humoral mechanism was clearly established by Reissmann (1950) who showed that the effect of anoxia on red cell production could not be a direct one due to changes in blood gases, but was transmitted via the blood in rats joined in parabiosis. Both animals of each pair showed increased erythropoiesis, although only one was maintained in a state of hypoxia. The hormone, now termed erythropoietin, was demonstrated directly in plasma by Erslev (1953) and by Borsook et al. (1954) , and although conflicting claims have been made as to its role in pathological states there is little doubt that it is the primary, if not the sole, physiological regulator of red cell production.
The principal factor governing the production or release of erythropoietin appears to be oxygen content of arterial blood, presumably mediated via reduced tissue oxygen tension at certain sites. Many tissues have been shown to contain the hormone, but probably the most important source of the hormone in anemia is the kidney. Evidence as to the site of production of the hormone and factors influencing its release has been reviewed elsewhere (Penington 1963) .
Interest in the possible role of the hormone in the aetiology of polycythemia was a natural consequence of the work of Reissmann. Linman & Bethell (1957) claimed to have demonstrated the hormone in the plasma of 2 patients with polycythaemia vera and in 2 with respiratory polycythzemia. This led to considerable interest in the field, but later reports (Linman & Bethell 1960 ) throw doubt on their claim to be measuring the physiological hormone. Their humoral factor was reported to produce reticulocytosis with abnormal microcytes, but to have no effect on haemoglobin synthesis. Unlike erythropoietin, their factor was stable to prolonged heating and soluble in lipid solvents. It ha.s not been possible to reproduce their experimental results using plasma from patients with polycytheemia vera (Penington, unpublished) and their findings remain unexplained. Before considering detailed findings of erythropoietin in clinical polycythaemia it is necessary to review the basic physiological relation between erythropoietin production and the circulating hemoglobin level. All studies reported below are based on the use of the hypertransfused rat for assay of erythropoietin, red cell production being measured in the recipient animals by determining utilization of a tracer dose of radioactive iron, 59Fe, at twenty-four hours (Penington 1961).
Relation ofErythropoietin to Haemoglobin Concentration in Normal and Ana?mic Subjects
Erythropoietin may be readily demonstrated in the plasma of patients with severe anemia due to many causes, with the notable exception of that associated with renal failure (Penington 1961). Following correction of the anemia by transfusion, the erythropoietic activity of the plasma may be shown to fall slowly over the course of three to four days. Fig 1 shows the result of such a study in a patient with aplastic anemia given two transfusions of packed red cells. The slow disappearance of the hormone probably reflects a long half-life in plasma. The effect of repeated venesection producing anaemia in a normal subject is shown in Fig 2. In this study the plasma was concentrated as described previously (Penington 1961) . Using this technique, erythropoietin could not be demonstrated in normal human plasma but a significant increase in erythropoietin was shown once the hemoglobin had fallen below 1 3g/ lOOml. From these studies and observations on patients with anamia of varying severity (Penington 1963) it has been found that the increase in erythropoietin in plasma mounts only slowly as the hemoglobin concentration falls through the range from normal to approximately 9 g/100 ml, but with more severe anaemia very high titres of erythropoietin are found (Fig 3) . With present bioassay techniques it is not possible to achieve accurate measurements of the low titres of erythropoietin found in the range of hemoglobin 9-13 g/100 ml, but a mild increase in erythropoietin of this order would be sufficient to increase bone marrow activity appreciably above the normal level (note increase in reticulocytes in the normal subject, Fig 2) . Slight or indefinite rises of erythropoietin above normal therefore do not rule out the possibility that a polycythemia is mediated by the hormone.
Erythropoietin in Normal Plasma
In earlier studies erythropoietin could not be demonstrated in plasma from normal human subjects (Penington 1961) . Increasing the volume of plasma injected into the assay animals resulted in hamolysis in the rats, but this was overcome by incubation of the plasma with washed rat erythrocytes to remove the species antibody. 4-1 (5) >0-05 101(5) <0 001 2-7(7) DL 7-5 (2) <0 01 3-2 (3) CWA 50 (2) > 0 05 7-3 (3) <0 01 3-2 (4) DFS 3 0(4) >0 05 7 5 (3) <0 01 2-3 (7) BT I 56(3) <005 7 6(4) <001 9 6(4) <001 24 (6) Following this procedure increased dosage of plasma from normal subjects did reveal erythropoietic activity in the plasma (Table 1) . This was equivalent to erythropoietin in a dose of 0 04 to 0 1 international units per ml.
Effect of Transfusion on Erythropoietin in the Normal Subject
Polycythiemia was induced in a normal subject by the transfusion of packed red cells from 2,000 ml of blood (Fig 4) . Reticulocytes were counted daily (counting 10,000 red cells) and the transfusion resulted in a reduced reticulocyte count. Erythropoietin was demonstrated readily in the initial plasma sample but was not present in plasma on Day 6. The assay on the sample from Day 4 showed erythropoietin in quantity comparable to the initial level, but the assay was carried out in only 3 rats and should not be regarded as quantitatively accurate. The induction of polycythemia by transfusion slows erythropoiesis, therefore, and removes erythropoietin from the plasma in the normal subject.
Erythropoietin in Polycythwmia due to Hypoxia Erythropoietin may be readily demonstrated in the plasma of patients with severe respiratory hypoxia, regardless of whether or not polycythemia is present (Freedman & Penington 1963) . Not all patients with hypoxic respiratory failure develop polycythemia, but the increase in erythropoietin appears to be fairly uniform, the marrow response to the hormone being variable, a finding which remains unexplained.
Erythropoietin in Polycytheemia Vera
Using the standard bioassay procedure described earlier (Penington 1961) , no significant increase in erythropoietin could be demonstrated in the plasma of 5 cases of polycythemia vera (Table 2) , but in one a questionable increase was found. If erythropoietin plays no part in the polycythaemia the plasma content of the hormone would be expected to be below normal as in the transfused normal subject. When plasma erythropoietin is assayed by the more sensitive technique used to demonstrate activity in normal plasma, activity was demonstrated in the plasma of a patient with polycythvmia vera comparable to that found in the normal subject (Table 3) . This failure of the secretion of the hormone to 'shut off' with polycytheemia remains unexplained.
Erythropoietin in Tumour and Renal Polycytheemia
The occurrence of a pure erythrocytosis with benign renal lesions and with tumours of kidney, uterus, liver and with cerebellar haemangioblastoma has been reviewed elsewhere (Penington 1962 (Penington , 1965 .
Assay of erythropoietin in the plasma in such cases shows levels above normal in some, but not all ( Table 2 ). The results suggest that the erythrocytosis found on occasions with renal cysts and hydronephrosis is mediated by increased erythropoietin secretion probably due to disordered renal blood supply, and it appears likely that renal carcinoma itself can secrete erythropoietin. The positive assay in the case of hepatoma with erythrocytosis suggests that this tumour also can, on occasions, produce the hormone or influence its secretion. Negative assay results do not exclude erythropoietin as the mechanism of a polycythaemia in view of the insensitivity of the assay. Using the more sensitive assay procedure for comparison of activity with that in normal plasma, some activity was shown in the plasma of a patient with erythrocytosis associated with a massive uterine fibroid and in another with erythrocytosis accompanying a brain-stem lesion of presumed vascular pathology. However, as similar activity was demonstrated in the plasma of a patient with polycythaemia vera, the significance of these findings remains uncertain.
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Conclusion
Erythropoietin mediates the response of the bone marrow to aneemia and hypoxia, and provides the mechanism of erythrocytosis in respiratory failure. Increased erythropoietin secretion in certain patients with benign renal lesions appears also to account for the erythrocytosis which may occur with these conditions, and renal carcinoma in some instances appears to be capable of secreting the hormone and producing erythrocytosis. The same appears to be true of hepatic carcinoma. It is uncertain whether the same mechanism applies in cerebellar haemangioblastoma and uterine fibroid, both of which may be associated with erythrocytosis and cured by removal of the tumour.
A failure of suppression of erythropoietin secretion could be a contributory factor increasing erythropoiesis in polycythaemia vera but is not the primary cause.
